Valneva's Stock Caught Between Revenue Slide and Lock-Up Overhang as Analysts Deliver Dueling Calls

Valneva shares tank 42% in 2025 as commercial revenue drops 37%, lock-up expires; Goldman downgrades to Sell, Jefferies bullish on Lyme vaccine VLA15.

Valneva's shares continue to languish near their lowest point in a year, battered by a sharp drop in commercial revenue and the expiry of a lock-up period on shares issued in April. The stock closed at €2.22 on Friday, down 2.97% on the day and just 4% above the 52-week trough of €2.13. Since the start of 2025, the French vaccine maker has shed 42.18% of its value.

The most immediate pressure came on July 2, when the lock-up restriction on shares distributed in April expired, adding a technical overhang to an already stretched equity. At the same time, Valneva's core business is bleeding. First-quarter revenue plummeted 37.2% to €30.9 million from €49.2 million a year earlier, while the net loss ballooned 249% to €32.1 million. All three marketed products — IXIARO, DUKORAL and IXCHIQ — posted lower sales.

Management has responded with a sweeping cost-reduction plan. The company intends to cut 10% to 15% of its global workforce and reduce operating expenses by 25% to 35% in 2026 compared with 2025 levels. The revenue outlook has also been trimmed: product sales are now expected between €135 million and €150 million in 2026, down from the previous €145 million to €160 million forecast. Total revenue guidance remains unchanged, however, at €145 million to €160 million.

The deteriorating financials have driven a deep rift between two major banks. Goldman Sachs this week downgraded Valneva from Neutral to Sell and slashed its price target from €3.25 to €2.15 — almost exactly in line with Friday's close. The bank points to the withdrawal of the Chikungunya vaccine Ixchiq from the U.S. market and a missed secondary endpoint in the Phase III study of the Lyme disease candidate as reasons for caution.

On the other side, Jefferies reaffirmed its Buy rating with a price target of $15, roughly six times the current share price. The bank argues that the Lyme vaccine's efficacy data are strong enough to support a regulatory submission and eventual approval. The same clinical results that Goldman interprets as a warning sign, Jefferies sees as a warrant for a bullish stance.

At the heart of the debate is VLA15, the Lyme vaccine candidate developed with Pfizer. Phase III data showed robust efficacy with no safety concerns, and Pfizer has committed to filing for approval this year. The secondary endpoint miss has not deterred optimists, but skeptics question whether it could undermine the full efficacy story. The stock's next major catalyst will be that regulatory submission.

Beyond Lyme, Valneva is advancing a Shigella vaccine candidate, S4V2, now in mid-stage testing with results expected in 2026. The company also recently licensed a vaccine technology targeting ETEC bacteria from the University of Bergen and NORCE, though that early-stage project is unlikely to influence the stock in the near term.

Technically, the shares trade well below both their 50-day moving average of €2.39 and their 200-day average of €3.48. The 14-day relative strength index stands at 37.9, approaching but not yet firmly in oversold territory. With a market capitalization of roughly €449 million — a fraction of what Jefferies' $15 target implies — the stock reflects a deeply skeptical market.

For Valneva, the coming months are binary. Either Pfizer files the Lyme vaccine as promised and later Shigella data bolster the pipeline thesis, or the commercial headwinds and cash burn continue to erode confidence. Until one of those triggers materializes, the chasm between Goldman's €2.15 and Jefferies' $15 will remain the defining feature of this stock.